Skip to main content
Abbott India Ltd. logo

Abbott India Ltd. — Investor Relations & Filings

Ticker · ABBOTINDIA ISIN · INE358A01014 LEI · 5493008KZ9E3HFRN6T46 BSE.NS Manufacturing
Open in API
Filings indexed 448 across all filing types
Latest filing 2023-12-26 Regulatory Filings
Country IN India
Listing BSE.NS ABBOTINDIA

About Abbott India Ltd.

https://www.abbott.co.in

Abbott India Ltd. is a pharmaceutical entity focused on providing high-quality healthcare solutions through a diverse portfolio of trusted brands. The company specializes in several key therapeutic areas, including women's health, gastroenterology, cardiology, metabolic disorders, primary care, and the central nervous system. Its product range features well-known formulations such as Duphaston, Thyronorm, Udiliv, Vertin, and Digene. The organization leverages advanced manufacturing capabilities and an extensive distribution network to serve healthcare professionals and patients. It emphasizes science-based innovation and clinical excellence to address evolving medical needs. By maintaining a strong focus on patient outcomes and therapeutic efficacy, the company has established itself as a reliable provider of pharmaceutical products across various specialized and general medical segments.

Recent filings

Filing Released Lang Actions
Closure of Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter from Abbott India Limited addressed to the BSE Limited regarding the closure of the trading window for insiders in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. It specifies the dates for the trading window closure around the announcement of unaudited financial results for the third quarter and nine months ending December 31, 2023. The document is a regulatory announcement related to insider trading compliance and trading restrictions, not a financial report, earnings release, or management discussion. It does not contain financial data or detailed report content but is a formal notification to the stock exchange and related parties. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2023-12-26 English
Resignation of Mr Vivek V Kamath as Managing Director and Director of the Company.
Board/Management Information Classification · 100% confidence The document is a formal notification to the stock exchange about the resignation of the Managing Director of Abbott India Limited. It references Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which pertains to disclosure of material events including changes in key managerial personnel. The content focuses on the resignation event, providing details such as the effective date and regulatory references. There is no financial data, report, or presentation included. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2023-12-19 English
Pursuant to Regulation 47 of the SEBI (LODR) Regulations, 2015, please find enclosed the newspaper cuttings of the Unaudited Financial Results of the Company for the second quarter and ....
Regulatory Filings
2023-11-10 English
Related Party Transactions for the half year ended September 30, 2023
Regulatory Filings Classification · 95% confidence The document is a disclosure of Related Party Transactions for the half year ended September 30, 2023, as required under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. It contains detailed tabular data on transactions with related parties, including purchase and sale of goods, loans, reimbursements, dividends, and remuneration. The document is addressed to the stock exchange and signed by the company secretary, indicating it is a regulatory disclosure. It is not a full financial report like an Annual Report or Interim Report, nor is it a simple announcement or certification. The content fits best under Regulatory Filings (RNS) as it is a compliance disclosure mandated by a regulatory body and does not constitute a full financial or management report.
2023-11-09 English
Unaudited Financial Results of the Company for the second quarter and half year ended on September 30, 2023
Regulatory Filings
2023-11-09 English
Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose a text of Unaudited Financial ....
Regulatory Filings
2023-11-09 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.